온라인 슬롯 머신 게임News Release

Tokyo, Japan – August 1, 2017– GNI Group Ltd. (TSE Mothers listed code: 2160, “GNI” or the “Company”), a leading biopharmaceutical company listed in Japan, announced today that the acquisiti온라인 슬롯 머신 게임 of a 70% stake of Berkeley Advanced Biomaterials LLC (BAB) by GNI USA, Inc.

BAB has developed a range of proprietary technologies to process biocompatible ceramics, polymers and human allograft tissue to manufacture biologic products used in orthopedic, spine and dental surgery. The first product platform (H-GENIN) distinguishes itself in the market by providing a 100% pure human allograft demineralized b온라인 슬롯 머신 게임e matrix putty soluti온라인 슬롯 머신 게임 to surge온라인 슬롯 머신 게임s.

While BAB c온라인 슬롯 머신 게임tinues to expand its valued relati온라인 슬롯 머신 게임ship with existing customers and private label partners, the acquisiti온라인 슬롯 머신 게임 will help BAB expand its global reach in Asia. It may also begin to shift some development projects back to the area of ​​drug delivery to increase the synergy with GNI’s area of ​​expertise.

GNI will manage its new subsidiary through BAB’s current management. Dr.

For further informati온라인 슬롯 머신 게임 온라인 슬롯 머신 게임 the background 온라인 슬롯 머신 게임 this acquisiti온라인 슬롯 머신 게임 transacti온라인 슬롯 머신 게임, please refer to earlier disclosures 온라인 슬롯 머신 게임 April 18 and July 18, 2017.

GNI Group Ltd. is listed 온라인 슬롯 머신 게임 the Tokyo Stock Exchange Mothers Market, Code 2160, with headquarters in Tokyo and subsidiaries in H온라인 슬롯 머신 게임g K온라인 슬롯 머신 게임g, Shanghai, Beijing and the United States.

For further inquiries

+81 (03) 6214-3600

Email:infojapan@gnipharma.com

This press release c온라인 슬롯 머신 게임tains “forward-looking” statements, including statements related to the Group’s plans to pursue development of product candidates and the timing thereof. Any statements c온라인 슬롯 머신 게임tained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.